Liposome Tech regulatory update

The FDA’s Oncology Drug Advisory Committee will review LTIZ’s DOX-SL on Feb. 14 as a single agent therapy for Kaposi’s sarcoma in AIDS patients who cannot tolerate or have failed conventional systemic...